VTV THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.57 USD | +3.10% |
|
+10.52% | +131.04% |
| Mar. 14 | VTv Therapeutics Inc. Announces Board Changes | CI |
| Mar. 13 | VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2022 | 2.02M | Sales 2023 | - | Capitalization | 23.43M |
|---|---|---|---|---|---|
| Net income 2022 | -19M | Net income 2023 | -20M | EV / Sales 2022 | 21.1 x |
| Net cash position 2022 | 11.42M | Net cash position 2023 | 8.98M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.59
x | P/E ratio 2023 |
-1.18
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 41.41% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.06% | ||
| 1 week | +4.16% | ||
| Current month | +9.52% | ||
| 1 month | +19.36% | ||
| 3 months | +226.82% | ||
| 6 months | +49.48% | ||
| Current year | +124.09% |
1 week
23.93
25.89
1 month
22.0326.54
Current year
7.3830.99
1 year
7.3839.60
3 years
7.38115.20
5 years
7.38190.00
10 years
7.38560.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Sekhri
CEO | Chief Executive Officer | 66 | 22-07-31 |
Steven Tuch
DFI | Director of Finance/CFO | 56 | 22-12-07 |
Vanessa McDade
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Srini Akkaraju
BRD | Director/Board Member | 56 | Feb. 26 |
Paul Sekhri
CEO | Chief Executive Officer | 66 | 22-07-31 |
Richard Nelson
BRD | Director/Board Member | 54 | 20-11-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 26.57 | +3.10% | 602 |
| 24-04-25 | 25.77 | +1.06% | 1,576 |
| 24-04-24 | 25.5 | +2.10% | 5,602 |
| 24-04-23 | 24.98 | +2.21% | 4,442 |
| 24-04-22 | 24.44 | +1.64% | 2,994 |
Delayed Quote Nasdaq, April 25, 2024 at 04:30 pm EDT
More quotes
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +124.09% | 62.69M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.03% | 22.02B | |
| -17.84% | 20.9B | |
| -9.33% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- VTVT Stock
